Navigation Links
Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) and the Company's clinical collaborators will report updated Phase 2 clinical trial results for its lead cancer therapy product candidates at the upcoming annual meetings of The American Society of Clinical Oncology (ASCO) in Chicago and the American Society of Gene Therapy (ASGT) in Seattle.

"We have a stronger than ever, advancing pipeline of first-in-class cancer therapies generating exciting data that could change the way cancer is treated and fulfill the promise of molecularly targeted cancer therapy," said Robert E. Sobol, M.D., senior vice president of Medical and Scientific Affairs at Introgen. "We have multiple Phase 3 programs either underway or planned with the goal of bringing these therapies to market to provide new treatments for widely underserved patient populations that are effective, generally well tolerated and can be easily combined and act synergistically with standard therapies by or before the end of this decade."

ASCO

-- Final results of a phase II trial of patients with extensive stage small cell lung cancer (ES-SCLC) immunized with wild type -p53 transduced dendritic cells after first-line chemotherapy, Abstract #3012: Poster presentation on Sun., June 3, from 2:00 - 6:00 p.m. in room S102a at McCormick Place, by lead author Alberto Chiappori, M.D., H. Lee Moffitt Cancer Center and Research Institute.

-- Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck, Abstract #6057: Poster presentation on Mon., June 4, from 1:00 - 5:00 p.m. at McCormick Place by lead author John Nemunaitis, M.D., Mary Crowley Medical Research Center and poster presentation by Robert Sobol, M.D., Introgen Therapeutics, Inc.

ASGT

-- Role of the Immune Sy stem in Replicating Adenovirus Using a Permissive Immune Competent Syrian Hamster Model, William Wold, Ph.D., St. Louis University School of Medicine: Presentation on Thurs., May 31, from 9:30 - 11:30 a.m. at Washington State Convention Center during symposium titled "Cancer: Hot Topics in Cancer Gene Therapy"

-- MDA-7 (INGN-241) Kills Chemoresistant Cancer Cells and Restores Chemosensitivity to Cisplatin, Abstract #197: Presentation during "Cancer: Apoptosis and Suicide" poster session on Thurs., May 31, from 5:00 - 8:00 p.m. at Washington State Convention Center by Rajagopal Ramesh, Ph.D., M. D. Anderson Cancer Center

-- Effect of Pre-existing Anti-Adenovirus Immunity and Anti-Tumor Immunity on the Efficacy of Adenovirus Vectors in Immunocompetent Syrian Hamster Model, Abstract #668: Presentation during "Immune Responses to Adenoviral Vectors" poster session on Fri, June 1, from 5:15- 8:15 p.m. in Hall 4AB at Washington State Convention Center by Debanjan Dhar, St. Louis University School of Medicine

-- Anticancer Activity of Oncolytic Adenovirus Vector Armed with IFN-alpha and ADP is Enhanced by Pharmacologically-Controlled Expression of TRAIL, Abstract #588: Presentation during "Cancer Immunotherapy II" poster session on Fri., June 1, 2007 from 5:15 - 8:15 p.m. in Hall 4AB at Washington State Convention Center by Elena V. Shashkova, VirRx, Inc.

-- Clinical Experience with the mda-7/IL-24 Tumor Suppressor, Abstract # 380: Presentation during "Tumor Suppressor and Targeted Gene Therapy" poster session and oral presentation on Friday, June 1, 2007 at 8:45 a.m. at the Washington State Convention Center by Sunil Chada, Ph.D., Introgen Therapeutics, Inc.

About Introgen Therapeutics, Inc.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutic s, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its ADVEXIN, INGN 241, and INGN 007 clinical development programs. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: www.introgen.com.

Contact

Introgen Therapeutics, Inc., Austin
C. Channing Burke, 512-708-9310, ext. 322
c.burke@introgen.com


'"/>




Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
3. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Genetic Analysis Systems Enter the Clinical Mainstream
7. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
8. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
9. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... 2016 Research and Markets ... Electronics 2015-2025: Applications, Technologies, Forecasts" report to ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, Composite ... Structural electronics involves electronic and/or electrical components and ... dumb structures such as vehicle bodies or conformally ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
Breaking Medicine Technology:
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):